ϳԹ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ϳԹ News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jul 9 2020

Full Issue

'Ethical Heartburn': FDA Official Pauses Over Safety Of Exposing Vaccine Trial Patients To COVID

In human challenge studies, people are exposed to the disease. But no cures exist for COVID-19, lethal to vulnerable patients. “If something bad happens, you don’t have a perfect fix for it,” said the FDA's Peter Marks. News on vaccines is on how to volunteer, how it will get to market and more.

A top FDA official overseeing vaccine approvals raised doubts Wednesday about the possibility of intentionally infecting people with the coronavirus to see whether vaccines work, saying that could represent “ethical heartburn” because there's still no easy way to treat the potentially severe disease. (Owermohle, 7/8)

Federal officials have repeatedly expressed optimism that at least one vaccine against the novel coronavirus will be proven effective and ready for market by early 2021. As of July 7, pharmaceutical companies worldwide were working on 160 candidate vaccines, including 21 that are being tested in people, according to the World Health Organization. ... Each prospective vaccine goes through three phases of study in humans. To speed the process, some vaccine developers are conducting two of the phases simultaneously. Here’s an overview of each phase. (Freyer and Saltzman, 7/9)

The U.S. government is investing $42 million to help Becton, Dickinson and Company, known as BD, ramp up its production of syringes and needles ahead of the future coronavirus vaccination push. The U.S.’s Biomedical Advanced Research and Development Authority (BARDA), committed to providing $42 million for a $70 million project to expand BD’s manufacturing operations in Nebraska, according to a press release. (Coleman, 7/8)

With new daily case counts of novel coronavirus on the rise in nearly every state, as well as Puerto Rico, the consequences of reopening much of the country without first stopping the spread has made one thing clear: An unlocked United States will likely continue to suffer from the deadly virus until a safe and efficient vaccine is finally distributed to a majority of the population. There are lots of different ways to formulate a vaccine, and all of them are now being considered for coronavirus. Some vaccines use common methods to confer immunity, while others are entirely experimental — they’ve never before been approved for use. (Isaacs-Thomas, 7/8)

If you want to be one of the first to receive an experimental vaccine for Covid-19, now's your chance. Wednesday, a new website -- coronaviruspreventionnetwork.org -- went live allowing people in the United States to register to take part in clinical trials for vaccines. The website will handle registration for the four large vaccine studies that are expected to start this summer and fall, and any others that follow. (Cohen, 7/8)

In other vaccination news —

Kaiser Health News: Shingles Vaccination Rate Soars But Leaves Many Behind 

Worried about the high cost of the copayment for the shingles vaccine, Jacky Felder, a Medicare beneficiary, opted against getting immunized last year. Last month, the Green Bay, Wisconsin, woman developed the disease, which left a painful, itchy rash across her abdomen. “Luckily, I’ve had a relatively mild case, but it’s been a week and half with a lot of pain,” said Felder, 69. (Galewitz, 7/9)

Sri Lanka and Maldives have become the first two countries in the World Health Organization’s South-East Asia region to eliminate both measles and rubella ahead of a 2023 target, the U.N. health agency announced Wednesday. (Mallawarachi, 7/8)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ϳԹ
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF